Navigation Links
BSI-201 Demonstrates Significant Tumor Growth Inhibition and Increased Survival Rates in Preclinical Ovarian Cancer Studies
Date:4/14/2008

- BiPar Sciences Presents First Peer-Reviewed Preclinical Results for

BSI-201 at 2008 AACR Annual Meeting -

SAN DIEGO, April 14 /PRNewswire/ -- BiPar Sciences, Inc. today announced positive preclinical data demonstrating the activity of its lead poly ADP-ribose polymerase (PARP) inhibitor, BSI-201, in ovarian cancer models. The results highlight the anti-tumor activity of BSI-201 through PARP activity inhibition, tumor growth suppression, and extended survival in multi-drug resistant xenograft models of ovarian cancer.

"We are excited to share emerging data on the therapeutic potential of BSI-201 as a novel oncology platform drug, in the area of DNA repair inhibition," said Hoyoung Huh, M.D., Ph.D., President and CEO of BiPar Sciences. "BSI-201 represents an innovative therapeutic candidate which is well positioned as both monotherapy and combination treatment in multiple solid tumor settings including ovarian cancer."

The data presented at the 2008 American Association for Cancer Research (AACR) Annual Meeting today, evaluated BSI-201 as both a single agent and in combination with topotecan in human OVCAR-3 xenografts resistant to adriamycin, melphalan and cisplatin. Administered as monotherapy, BSI-201 demonstrated significant tumor growth delay and improved survival. In combination with topotecan, BSI-201 significantly inhibited tumor growth and increased the percentage of complete tumor regressions, compared with topotecan alone.

Based on the preclinical findings and positive Phase 1 results, BiPar is currently enrolling in a clinical trial of BSI-201 in combination with topotecan in advanced ovarian cancer and will soon launch a Phase 2 monotherapy trial in BRCA-negative ovarian cancer patients. These ovarian cancer trials represent an important expansion of BiPar's on-going Phase 2 programs in breast and brain cancer patients.

About BSI-201

BSI-201, a novel DNA repair inhibitor of PARP, is Bi
'/>"/>

SOURCE BiPar Sciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. BiPar Sciences Expands Clinical Program for BSI-201, a Novel DNA Repair Inhibitor, in Brain Cancer
2. Poniard Pharmaceuticals Oral Picoplatin Demonstrates Positive Bioavailability in Ongoing Phase 1 Trial
3. CorMatrix(R) Announces Intramyocardial Injection of Emulsified ECM Technology(TM) Demonstrates Enhanced Angiogenesis and Improved Cardiac Function in a Preclinical Model
4. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
5. Landmark ONTARGET(TM) Trial Demonstrates Micardis(R) is Equally Effective as Ramipril, with Fewer Discontinuations, in a Broad High-Risk Cardiovascular Population
6. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
7. ANX-201 Demonstrates a Unique Resistance Profile in Preclinical Tests
8. GSK Cervical Cancer Candidate Vaccine CERVARIX (R) Demonstrates Long-Term Protection for More Than Six Years
9. IDX899 Demonstrates Rapid and Profound Inhibition of HIV Replication in a Phase I/II Clinical Trial in Treatment-Naive HIV-Infected Patients
10. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
11. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 2014  Advanced Medical Isotope Corporation ("AMIC") (OTCQB: ADMD), ... the development of brachytherapy devices and medical isotopes ... it has filed a de novo ... for marketing clearance for its patented Y-90 RadioGel(TM) ... Food, Drug and Cosmetic Act (the "Act").  ...
(Date:12/24/2014)... 23, 2014   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today announced ... the Marketing Authorization Application (MAA) for sebelipase alfa ... company,s request for accelerated assessment, which has the ... The MAA, and the Biologics ...
(Date:12/24/2014)... , Dec. 23, 2014  The American Diabetes ... pressure target for people with diabetes and that ... high doses of statins, in keeping with recent ... by the American College of Cardiology (ACC) and ... in the most recent changes to the Association,s ...
Breaking Medicine Technology:Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 2Advanced Medical Isotope Corporation Files a "de novo" Submission for Y-90 RadioGel(TM) Device 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
... , May 13 Pacific Bridge Medical, a leading Asia ... on May 26, 2010 at 11am EDT . , ... Taiwan is the sixth largest pharmaceutical market in the ... a solid national health care system. This webcast will give an overview of ...
... , SEATTLE , May 13 ... company, today announced that, based on successful preclinical studies, ... MASP-2 antibody program and has initiated the cGMP manufacturing ... have shown that Omeros, proprietary, fully human, monoclonal MASP-2 ...
Cached Medicine Technology:Pacific Bridge Medical to Host Taiwan Drug Registration Webinar 2Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders 2Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders 3Omeros Selects Clinical Candidate for MASP-2 Program With Potential Applicability to Multiple Inflammatory Disorders 4
(Date:12/24/2014)... 24, 2014 (HealthDay News) -- Adults who experienced ... of migraine headaches, suggests a study published online ... "Childhood maltreatment can have long-lasting effects, like ... adulthood," study author Dawn Buse, director of behavioral ... City, said in a journal news release. ...
(Date:12/24/2014)... HealthDay Reporter WEDNESDAY, Dec. 24, ... start smoking or drinking with each additional symptom they ... new research suggests. "Our findings underscore the ... use as [these] children approach adolescence," said study author ... Group, which is part of Cincinnati Children,s Hospital. "This ...
(Date:12/24/2014)... Reinberg HealthDay Reporter TUESDAY, ... American Diabetes Association (ADA) call for giving the cholesterol-lowering drugs ... prevent heart disease. These new standards bring the association ... Heart Association, which also recommend giving low- or high-dose statins ... with diabetes. "We agree that the decision to start ...
(Date:12/24/2014)... For chic ladies, new fashionable outfits are necessary when ... Holiday Wish List, Angeldress.co.uk has chosen some of ... ladies’ holiday wardrobe by launching a promotion on its cheap ... discount of 80% off, like a cheap suit. , “All ... chic wedding dresses are among the hottest items in the ...
(Date:12/24/2014)... December 24, 2014 Dr. Svetlana Gomer, ... across the nation gathered with US Marines on November ... raise funds for the Toys for Tots Literacy Program. ... thousands of new books and audio books for the ... underprivileged children this Christmas. It represents another major strike ...
Breaking Medicine News(10 mins):Health News:Abuse in Childhood Tied to Migraines in Adulthood 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 2Health News:ADHD May Raise Teens' Odds for Smoking, Drinking 3Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 2Health News:Nearly All Diabetics Should Be on Cholesterol-Lowering Drugs: Experts 3Health News:Angeldress.co.uk Starts Its Big Sales by Offering Various Kinds of Cheap Clothes and Fashion Accessories 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 2Health News:Dr. Svetlana Gomer, MGS Tewksbury Dental and Other Dentists Working With the U.S. Marines Strike Again In the Battle Against Illiteracy 3
... and MDS Pharma Services, Goodwill, , ... (TSX: MDS; NYSE: MDZ ), a leading provider of ... update for fiscal 2008 performance. , Based on preliminary ... the range of $1,210 million to $1,220 million and adjusted EBITDA ...
... Congress are determined to complete the job started around 1900 and ... They plan to move fast, seize momentum, and not let go. ... on the offense," said former South Dakota Senator Tom Daschle, presumptive ... , The bill might well be S. 1, and ...
... plc (NASDAQ:, ICLR )(ISIN:IE0005711209), a global ... biotechnology and medical device industries,today announced that ... new cardiac,echocardiography analysis software solution. The software, ... viewed, measured and interpreted,in clinical trials and ...
... spending hundreds of millions annually to prevent dry skin... much of the ... can be taken to heal and protect the skin. , ... Denver, ... of the year for scores of people across the country suffering from ...
... out of Wake Forest University School of Medicine and the ... popular class of oral diabetic drugs doubles the risk of ... findings appear online today on the Web site for the ... the January 6 issue. , "We knew going into this ...
... highlights from the December issue of Mayo Clinic Women,s HealthSource ... Mayo Clinic Women,s HealthSource attribution is ... subscription information as your editorial policies permit: Visit www.bookstore.mayoclinic.com ... , , Who,s ...
Cached Medicine News:Health News:MDS Provides Update on Fiscal 2008 Performance 2Health News:MDS Provides Update on Fiscal 2008 Performance 3Health News:MDS Provides Update on Fiscal 2008 Performance 4Health News:Blitzkrieg Declared On American Medicine 2Health News:Blitzkrieg Declared On American Medicine 3Health News:ICON Medical Imaging Launches New Cardiac Echocardiography Analysis Software 2Health News:Top Tips To Naturally Heal Dry Skin And Moisturize This Winter 2Health News:Top Tips To Naturally Heal Dry Skin And Moisturize This Winter 3Health News:Popular class of diabetes drugs doubles risk of fractures in women 2Health News:Popular class of diabetes drugs doubles risk of fractures in women 3Health News:December 2008 Mayo Clinic Women's HealthSource Highlights Happiness, Dementia and Smoking 2Health News:December 2008 Mayo Clinic Women's HealthSource Highlights Happiness, Dementia and Smoking 3Health News:December 2008 Mayo Clinic Women's HealthSource Highlights Happiness, Dementia and Smoking 4Health News:December 2008 Mayo Clinic Women's HealthSource Highlights Happiness, Dementia and Smoking 5
... The SkanWasher 400 is ... microplate washer with built-in ... The individual pressure settings ... very gentle wash to ...
Lab-Reader...
Fully automatic NRTL and CE certified microplate reader....
... a compact and versatile multilabel ... design allows up to six ... counting, luminescence, absorbance, and fluorescence ... and fluorescence polarization all on ...
Medicine Products: